Trizedon MR

Adjunctive to established antiangina.

1 tab twice daily. Elderly/patient w/ moderate renal impairment (CrCl 30-60 mL/min) Recommended dose: 1 tab in the morning during breakfast.

Should be taken with food: Take during breakfast.

Hypersensitivity. Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, & other related movement disorders. Severe renal impairment (CrCl <30 mL/min). Use in nursing mothers is generally inadvisable.

Should not be used as monotherapy. Benefit of the treatment should be assessed after 3 mth, & should be discontinued if there is no treatment response. This drug is not a curative treatment for angina attacks, nor is it indicated as an initial treatment for unstable angina, or MI, nor in the pre-hospital phase or during the 1st day of hospitalization. In the event of an angina attack, the coronaropathy should be reevaluated & an adaptation of the treatment considered. Trimetazidine can cause or worsen Parkinsonian symptoms (tremor, akinesia, hypertonia), which should be regularly investigated, especially in elderly patients. Falls may occur, related to gait instability or hypotension, in particular in patients taking antihypertensive treatment. Contains an active substance which may give a +ve reaction in doping test in athletes. Moderate renal impairment. Not recommended in patients w/ severe hepatic failure. Avoid use during pregnancy. Elderly >75yr.

Dizziness, headache; abdominal pain, diarrhoea, dyspepsia, nausea, vomiting; rash pruritus, urticaria; asthenia.

Anti-Anginal Drugs

C01EB15 - trimetazidine ; Belongs to the class of other cardiac preparations.

K